Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries. Subscribe for free now.
Field Trip’s Co-founder and Executive Chairman Ronan Levy on investor opportunities following Nasdaq listing; Cybin to list on NYSE’s Small Cap Market to finance expansion; The Times: Psychedelic firms take a trip over the Atlantic in search of funds. Read more in Issue 39 of the Psychedelics Newsletter.
Data science driving innovation in psychedelic medicine; Looking back on the PSYCH Investor Summit: Research & Development; atai Life Sciences’ Founder warns decriminalisation could set back regulation. Read more in Issue 37 of the Psychedelics Newsletter.
PSYCH Investor Summit: Research & Development kicks off today; Tryp Therapeutics to treat psychiatric disorders; Braxia Scientific identifies short-term ROI in psychedelic medicine. Read more in Issue 36 of the Psychedelics Newsletter.
One week remains until the PSYCH Investor Summit: Research & Development; Texas legalises medical psychedelic research; Compass Pathways conducts world’s largest psilocybin trial to-date. Read more in Issue 35 of The Psychedelics Newsletter.
Awakn Life Sciences lists on the NEO Exchange; examining psychedelic revenue opportunities within tight regulations; IPOs build momentum as atai Life Sciences goes public. Read more in Issue 34 of The Psychedelics Newsletter.
Examining the business impact of North American psychedelic drug regulations; atai Life Sciences targets US$2.3 billion IPO valuation; and democrats introduce a bill to end the War on Drugs. Read more in Issue 33 of The Psychedelics Newsletter.
For-profit or non-profit? That is the ($100-billion) question. Rick Doblin and Christian Angermayer join the 7 July PSYCH Investor Summit: Research and Development to discuss the role of non and for-profit businesses in a can’t-miss conversation. Read more in Issue 31 of The Psychedelics Newsletter.
Dr. Carl Hart on the impediment of prolonged research; Field Trip appoints former US Senate Majority Leader as Special Adviser and Cybin studies sublingual psilocybin for major depressive disorder. Read more in Issue 30 of The Psychedelics Newsletter.
Announcing the next PSYCH Investor Summit: Research & Development, MindMed hits the NASDAQ and exploring the use of psychedelics to treat addiction. Read more in Issue 26 of The Psychedelics Newsletter.
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.
The first-ever ketamine-assisted psychotherapy clinic has opened in the UK while Field Trip Health has confirmed the closing of $95m of funding. All this and more in Issue 20 of The Psychedelics Newsletter.
Following a breakout year for the psychedelic sector, the pharmaceutical industry is set to take on a more prominent role in the market in 2021 and beyond. Learn more and catch up with the latest investment trends and scientific findings in Issue 13 of The Psychedelics Newsletter.
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction. All this and more in issue 12 of the PSYCH Newsletter.
Gain access to every panel discussion from The PSYCH Symposium before time runs out and catch up on the latest news from across the international psychedelics industry in Issue 11 of The Psychedelics Newsletter, here.
A petition to legalise natural psychedelics in Canada reaches 13,000 signatures, and a Congressman has said psychedelics show promise in treating PTSD as Oakland activists also unveil guidelines for psychedelic healing ceremonies.
Canada approves end-of-life psilocybin treatment for palliative patients while UK scientists and experts propose easing restrictions for medical psychedelics and Californian activists propose easing restrictions for medical psychedelics.
An attempt to block the Washington D.C. psychedelic initiative fails, therapists request approval to test psychedelics in Canada and Oregon gets set to vote on psilocybin for therapeutic use in November 2020.
Oregon psilocybin decriminalisation campaign and DC activists say they will qualify for the November ballot while the New Medical Psychedelics Working Group to lobby for ease in UK research restrictions.
THE LATEST INSIGHTS, STRAIGHT TO YOUR INBOX
Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.